Surgery Partners, Inc. (SGRY), a prominent player in the healthcare sector, has caught the attention of investors with its intriguing potential upside of 61.44%, according to analyst ratings. This company, headquartered in Brentwood, Tennessee, operates a network of surgical facilities and provides a wide range of ancillary services across the United States. With a market capitalization of $1.55 billion, Surgery Partners is positioned within the medical care facilities industry, offering specialized services such as orthopedics, pain management, ophthalmology, and more.
As of the latest trading session, Surgery Partners’ stock is priced at $11.98, with a modest price change of 0.18, reflecting a 0.02% increase. The stock has experienced a significant 52-week range, fluctuating between $11.80 and $24.39, indicating a volatile market presence. Despite the current price being near its 52-week low, the stock’s average target price from analysts stands at $19.34, suggesting substantial room for growth.
Valuation metrics for Surgery Partners reveal a forward P/E ratio of 27.18, which is essential for investors considering future earnings potential. However, traditional valuation measures such as the P/E (Trailing), PEG, and Price/Book ratios are currently unavailable, leaving investors to rely on other indicators.
The company has demonstrated a modest revenue growth of 2.40%, with an EPS of -0.61, highlighting some financial challenges. Despite this, Surgery Partners maintains a resilient return on equity of 2.76% and a robust free cash flow of approximately $164.7 million, reinforcing its financial stability and potential for reinvestment into business operations.
While Surgery Partners does not offer a dividend yield, its payout ratio remains at 0.00%, suggesting a focus on growth rather than immediate shareholder returns. This decision aligns with the company’s strategy to reinvest profits into expanding its surgical facilities and service offerings.
Analyst sentiment towards Surgery Partners is predominantly positive, with nine buy ratings and three hold ratings, and no sell ratings. The target price range spans from $14.00 to $25.00, supporting the optimistic outlook for the stock. Technical indicators present a mixed picture, with the 50-day and 200-day moving averages at $14.46 and $18.85, respectively, suggesting current trading below these averages. Meanwhile, an RSI of 20.79 indicates that the stock is in oversold territory, potentially signaling a buying opportunity for strategic investors.
Surgery Partners’ comprehensive suite of services, including ambulatory surgery centers, surgical hospitals, and ancillary offerings like physician practices and diagnostic testing, positions it uniquely in the healthcare landscape. As it continues to expand its footprint and service capabilities, investors are closely watching for signs of operational and financial improvement.
In the ever-evolving healthcare sector, Surgery Partners, Inc. presents a compelling case for investors seeking exposure to the medical care facilities industry. With a significant upside potential and a strategic focus on growth, this stock warrants consideration for those willing to navigate the inherent risks and volatility of the market.
